Immunotherapeutic strategies for the treatment of ovarian cancer: current status and future direction

• Published in: Journal of industrial and engineering chemistry (Seoul, Korea) Vol. 94; pp. 62 - 77
• Main Authors: Duwa, Ramesh, Jeong, Jee-Heon, Yook, Simmyung
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 25-02-2021; 한국공업화학회
• Subjects: Immune system; Immunotherapy; Liposomes; Nanoparticle; Ovarian cancer; Poly (lactic-co-glycolic) acid nanoparticles; T cells; 화학공학; TRA; EpCAM; TRA/α-PD-1 mAb; Nanoparticle; CLEC10A; MHC; HR; TNF; Ovarian cancer; IFN-α; IFN-γ; Poly (lactic-co-glycolic) acid nanoparticles; Th; GM-CSF; Immunotherapy; IC; MUC-1; PFS; CARs; CR2; CR1; IL; RECIST; CAR-T cells; OK-432; SIRPα; PGA; TNF- β; NA; IMCT; NK; PD-1; FDA; TCR; DCVAC; PLA; PRRs; IgG; PLD; NPL; T cells; FR; Cvac; DCs; LAG-3; CA125; PD-L1; CTLA-4; rIFN-γ1b; TIM-3; Immune system; APCs; MUC-CD; OS; SOC; Tregs; VEGF; siRNA; TME; mAb; MST; HMFG1; PLGA; PEI; TAA; mAbs; CTL; Liposomes; MOVL; TLRs
• ISSN: 1226-086X; 1876-794X
• DOI: 10.1016/j.jiec.2020.11.015

[Display omitted]
Ovarian cancer is the most significant cause of gynecological cancer mortality, with the majority of women with advanced disease. Although surgery and chemotherapy can enhance survival rates, the 5-year survival rates remain low at 45%. So, alternative treatment options need to be implemented to improve therapeutic outcomes. In the ovarian cancer tumor, the presence of T cells helps to improve the progression-free and overall survival, whereas a poor prognosis corresponds to the presence of regulatory T cells and expression of T cells inhibitory molecules. Analyzing the important role of these immune systems in cancer management, immunotherapy may create a sustained response to recurring ovarian cancer cells in the immune system. In addition, by boosting anti-tumor immune response, women’s prognosis with this lethal disease can be significantly influenced. Different immunotherapeutic strategies and nanoparticle-based strategies were used as potential treatment options to challenge tumor progression. This review discusses cytokine therapy, peptide vaccine, monoclonal antibody, dendritic cell-based vaccine, adoptive T cells transfer, and immune checkpoint inhibitors as well as different nanoparticles such as poly (lactic-co-glycolic) acid nanoparticles, polyethyleneimine-based nanoparticles, and liposomes that offer a new paradigm in the treatment of ovarian cancer.